Ponatinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 84 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page11 sections

Article Summary

Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.

Ponatinib is a tyrosine kinase receptor inhibitor that is used in the therapy of myelogenous (CML) positive for the Philadelphia chromosome. Ponatinib is commonly associated with transient elevations in serum aminotransferase levels during treatment, but with only rare instances of clinically apparent injury.

Ponatinib is a benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl benzoic acid with the aniline group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I). It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is an N-methyl piperazine, a member of benzamides, an acetylenic compound, an imidazopyridine, and a member of (trifluoromethyl)benzenes. It is a conjugate base of ponatinib(1+).

Ponatinib Hydrochloride is the hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.

Ponatinib hydrochloride is the hydrochloride salt of ponatinib. It is a potent pan inhibitor of tyrosine kinases, active in all single resistance ABL kinase mutations including the T315l mutation. It is approved for the treatment of chronic myeloid leukemia. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It contains ponatinib(1+).

Mechanism of Action

Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the of CML. This protein arises from the fused Bcr and Abl genes- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors, and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in size expressing native or T315I mutant BCR-ABL has been observed in rats.

or

Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors, and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR-ABL when compared to controls.

Gain-of-function mutations of membrane receptor tyrosine kinase KIT especially gate-keeper D816V point mutation in KIT render kinase auto-activation, , and poor . D816V KIT is found in -80% of the patients of mastocytosis (SM) and is resistant to the first and second generations of tyrosine kinase inhibitors (TKIs). The purpose of this investigation was aimed at explore whether ponatinib (AP24534), a novel effective TKI against T315I Bcr-Abl was active against D816V KIT. /The researchers/ discovered that ponatinib abrogated the phosphorylation of KIT harboring either V560G (sensitive to imatinib) or D816V mutation (resistant to imatinib) and the downstream signaling transduction. Ponatinib inhibited the growth of D816V KIT-expressing cells in culture and nude mouse xenografted tumors. Ponatinib triggered apoptosis by inducing the release of cytochrome c and AIF, downregulation of Mcl-1. Furthermore, ponatinib abrogated the phosphorylation of beta-catenin at site Y654, suppressed the translocation of beta-catenin, inhibited the transcription and DNA binding of TCF and the expression of its targets (e.g. Axin2, c-Myc, and cyclin D1). Moreover, ponatinib was highly active against xenografted D816V KIT tumors in nude mice and significantly prolonged the survival of mice with aggressive SM or mast cell leukemia by impeding the expansion and infiltration of mast cells with imatinib-resistant D814Y KIT.

Indications

  • Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
  • Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
  • Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
  • Treatment of acute lymphoblastic leukaemia, Treatment of chronic myeloid leukaemia
  • Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia.
  • Accelerated phase chronic myologenic leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Myeloid Leukemia, Chronic, Chronic Phase
  • Blast phase Chronic myelocytic leukemia

Contraindications

  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • high blood pressure
  • a
  • acute blood clot in the heart
  • slow heartbeat
  • supraventricular arrhythmias, a type of abnormal heart rhythm
  • chronic
  • sudden and serious symptoms of heart failure called acute decompensated heart failure
  • a blood clot in the brain
  • a
  • a weakening and ballooning in an wall called an arterial aneurysm
  • obstruction of a blood vessel by a blood clot
  • a blood clot in an artery
  • blood clot formation in
  • bleeding
  • blockage or closing off of blood vessels
  • damage to the liver and
  • recent operation
  • visible water retention
  • abnormal liver function tests
  • impaired wound healing
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • a rupture in the wall of the stomach or intestine
  • reactivation of B
  • a type of brain disorder called posterior reversible encephalopathy
  • dissection of artery

Strengths: 30 mg; 45 mg; 15 mg; 10 mg

Chronic Myelogenous Leukemia

Chronic phase chronic myeloid leukemia (CP-CML):

  • Initial Dose: 45 mg orally once a day
  • Upon achievement of 1% BCR-ABL1 or less (standardized according to International Scale): 15 mg orally once a day
  • For loss of response: Re-escalate to a previously tolerated dosage of 30 mg or 45 mg orally once a day

Accelerated phase chronic myeloid leukemia (AP-CML), blast phase chronic myeloid leukemia (BP-CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL):

  • Initial dose: 45 mg orally once a day
  • The optimal dose has not been identified for AP-CML, BP-CML, and Ph+ ALL.
  • Consider dose reduction for AP-CML patients who have achieved major cytogenic response.
  • Continue treatment until loss of response or unacceptable toxicity.
  • Drug discontinuation should be considered if patient response has not occurred by 3 months (90 days).
  • This drug is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML).
  • For the treatment of adult patients with CP-CML with resistance or intolerance to at least two prior kinase inhibitors
  • For the treatment of adult patients with AP-CML, or BP-CML or Ph+ ALL for whom no other kinase inhibitors are indicated
  • For the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL

Acute Lymphoblastic Leukemia

Chronic phase chronic myeloid leukemia (CP-CML):

  • Initial Dose: 45 mg orally once a day
  • Upon achievement of 1% BCR-ABL1 or less (standardized according to International Scale): 15 mg orally once a day
  • For loss of response: Re-escalate to a previously tolerated dosage of 30 mg or 45 mg orally once a day

Accelerated phase chronic myeloid leukemia (AP-CML), blast phase chronic myeloid leukemia (BP-CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL):

  • Initial dose: 45 mg orally once a day
  • The optimal dose has not been identified for AP-CML, BP-CML, and Ph+ ALL.
  • Consider dose reduction for AP-CML patients who have achieved major cytogenic response.
  • Continue treatment until loss of response or unacceptable toxicity.
  • Drug discontinuation should be considered if patient response has not occurred by 3 months (90 days).
  • This drug is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML).
  • For the treatment of adult patients with CP-CML with resistance or intolerance to at least two prior kinase inhibitors
  • For the treatment of adult patients with AP-CML, or BP-CML or Ph+ ALL for whom no other kinase inhibitors are indicated
  • For the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL

Liver Dose Adjustments

ANY LEVEL OF LIVER DYSFUNCTION (CHILD-PUGH A, B, OR C):

  • Reduce the initial dose to 30 mg once a day in patients with preexisting liver dysfunction (Child-Pugh A, B, or C) and monitor for adverse reactions.
  • The safety of multiple doses, or doses higher than 30 mg have not been studied in patients with hepatic impairment.

IF HEPATOTOXICITY DEVELOPS DURING TREATMENT:
Elevation of liver transaminase greater than 3 times the upper limit of normal (ULN) and if:

  • Occurrence at 45 mg: Interrupt dosing and monitor hepatic function; and resume treatment at 30 mg after recovery to Grade 1 or less (less than 3 x ULN)
  • AST or ALT at least 3 times ULN with an elevation of greater than 2 times ULN and alkaline phosphatase less than 2 times ULN: Discontinue treatment

Dose Adjustments

  • Patients with chronic phase myeloid leukemia who have achieved a 1% BCR-ABL1 or less (standardized according to International Scale) or patients with accelerated phase chronic myeloid leukemia who achieve a major cytogenetic response: Consider reducing the dose
  • If response to treatment has not occurred by 3 months: Consider treatment discontinuation

DOSAGE MODIFICATION FOR COADMINISTRATION OF STRONG CYP450 3A INHIBITORS/INDUCERS:

  • Concomitant use of strong CYP450 3A inducer: Avoid unless the benefit outweighs the risk and monitor for reduced efficacy; select a concomitant medication with no or minimal CYP450 3A induction potential if possible
  • Concomitant use of strong CYP450 3A inhibitors:
  • If current dose 45 mg once a day: Reduce dose to 30 mg once a day
  • If current dose 30 mg once a day: Reduce dose to 15 mg once a day
  • If current dose is 15 mg once a day: Reduce dose to 10 mg once a day
  • If current dose is 10 mg once a day: Avoid use
  • Resume the dosage that was tolerated prior to initiating the strong CYP450 3A inhibitor after the strong CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives.

RECOMMENDED DOSE REDUCTION FOR ADVERSE REACTIONS:

  • First Reduction: 30 mg orally once a day for CP-CML, AP-CML, BP-CML, and Ph+ ALL
  • Second Reduction: 15 mg orally once a day for CP-CML, AP-CML, BP-CML, and Ph+ ALL
  • Third reduction: 10 mg orally once a day for CP-CML and permanently discontinue for AP-CML, BP-CML, and Ph+ ALL patients unable to tolerate the second dose reduction
  • Subsequent reduction: Permanently discontinue treatment for CP-CML, AP-CML, BP-CML, and Ph+ ALL

HEPATOTOXICITY:
Elevation of liver transaminase greater than 3 times the upper limit of normal (ULN) and if:

  • Occurrence at 45 mg: Interrupt dosing and monitor hepatic function; and resume treatment at 30 mg after recovery to Grade 1 or less (less than 3 x ULN)
  • AST or ALT at least 3 times ULN with an elevation of bilirubin greater than 2 times ULN and alkaline phosphatase less than 2 times ULN: Discontinue treatment

ELEVATED LIPASE/PANCREATITIS:

  • Serum lipase greater than 1 to 1.5 x ULN: Consider treatment interruption until resolution and then resume at same dose
  • Serum lipase greater than 1.5 to 2 times ULN, 2 to 5 times ULN and , or asymptomatic radiologic pancreatitis: Interrupt until Grade 0 or 1 (less than 1.5 times ULN) and then resume at next lower dose
  • Serum lipase greater than 2 to 5 times ULN and symptomatic, symptomatic Grade 3 pancreatitis, or serum lipase greater than 5 times ULN and asymptomatic: Interrupt until complete resolution of symptoms and after recovery of lipase elevation Grade 0 or 1, then resume at next lower dose
  • Symptomatic pancreatitis and serum lipase greater than 5 times ULN: Discontinue treatment

MYELOSUPPRESSION:

  • ANC less than 1 x 10(9)/L or platelets less than 50 x 10(9)/L and if:
  • First Occurrence: Interrupt treatment and resume at same dose after recovery to ANC 1.5 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater
  • Recurrence: Interrupt treatment until resolution and then resume at next lower dose

ARTERIAL OCCLUSIVE EVENTS:
Cardiovascular or Cerebrovascular:

  • Grade 1: Interrupt treatment until resolved, then resume at same dose
  • Grade 2: Interrupt treatment until Grade 0 or 1, then resume at next lower dose and discontinue if recurrence
  • Grade 3 or 4: Discontinue treatment

Peripheral vascular and other or venous thromboembolic events:

  • Grade 1: Interrupt treatment until resolved, resume at same dose
  • Grade 2: Interrupt treatment until Grade 0 or 1, then resume at same dose and if recurrence, interrupt treatment until Grade 0 or 1, then resume at next lower dose
  • Grade 3: Interrupt treatment until Grade 0 or 1, then resume at next lower dose and discontinue if recurrence
  • Grade 4: Discontinue treatment

HEART FAILURE:

  • Grade 2 or 3: Interrupt treatment until Grade 0 or 1, then resume at the next lower dose and discontinue if recurrence
  • Grade 4: Discontinue treatment

OTHER NON-HEMATOLOGIC ADVERSE REACTIONS:

  • Grade 1: Interrupt treatment until resolved, then resume at the same dose
  • Grade 2: Interrupt treatment until Grade 0 or 1, then resume at the same dose, and if recurrence, interrupt until Grade 0 or 1, then resume at the next lower dose
  • Grade 3 or 4: Interrupt treatment until Grade 0 or 1, then resume at the next lower dose and discontinue if recurrence

Administration Advice:

  • This drug may be taken with or without food and at the same approximate time each day.
  • Swallow tablets whole; do not crush, break, cut, chew, or dissolve the tablets.
  • If a dose is missed, take the next dose at the regularly scheduled time the next day.
  • Do not take 2 doses at the same time to make up for a missed dose.
  • This drug contains lactose monohydrate, care, and close monitoring is recommended for intolerant patients.

Monitoring:

  • Monitor for evidence of arterial occlusive events and venous thromboembolic events.
  • Monitor for heart failure.
  • Monitor liver function tests at baseline, then at least monthly or as clinically indicated.
  • Monitor blood pressure at baseline and as clinically in indicated.
  • Monitor serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated.
  • Monitor for symptoms of peripheral and cranial neuropathy.
  • Monitor for vision at baseline and periodically during treatment.
  • Monitor for hemorrhage.
  • Monitor for fluid retention.
  • Monitor for signs and symptoms of arrhythmias.
  • Monitor blood counts every 2 weeks for the first 3 months and then monthly or as indicated for myelosuppression.

Patient Advice:

  • Advise the patient to read the approved patient labeling (Medication Guide).
  • Advise females of the potential risk to a fetus and inform their healthcare provider of a known or suspected pregnancy.
  • Advise females of reproductive potential to use effective contraception during treatment and for at least 3 weeks after the last dose.
  • Advise females of the potential for reduced fertility.
  • Advise not to breastfeed during treatment and for 6 days after the last dose.
  • Advise patients to inform of any planned surgical procedure.
  • Advise patients to immediately report any symptoms suggestive of a blood clot such as chest pain, shortness of breath, weakness on one side of the body, speech problems, leg pain, or leg swelling.
  • Advise patients to report any signs and symptoms suggestive of hemorrhages such as unusual bleeding or easy bruising.
  • Advise patients to report symptoms suggestive of heart complications such as chest pain, shortness of breath, hypertension, palpitations, dizziness, or fainting.
  • Advise patients to report any symptoms suggestive of pancreatitides such as nausea, vomiting, abdominal pain, or abdominal discomfort.
  • Advise patients to report any developing fluid retention such as leg swelling, abdominal swelling, weight gain, or shortness of breath.
  • Advise patients to report fever, infection, headache, seizure, altered mental status, and neurological disturbances.
  • Advise patients to report symptoms of liver problems such as jaundice, anorexia, bleeding or bruising.
  • Advise patients to avoid drinking grapefruit juice or eating grapefruit during treatment.
  • Inform patients that the tablets contain lactose monohydrate.
  • Advise patients to report symptoms of neuropathy such as hypo- and hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.
  • Advise patients to report symptoms of ocular toxicity such as blurred vision, dry eye, or eye pain.

Side Effects

The Most Common

  • rash
  • dry skin
  • diarrhea
  • constipation
  • hair loss
  • white patches or sores on the lips or in the mouth and throat
  • loss of appetite
  • weight loss
  • cough
  • difficulty falling asleep or staying asleep
  • back, bone, joint, limb, or muscle pain
  • unusual bruising or bleeding
  • bloody or black, tarry stools
  • blood in the urine
  • bloody vomit
  • unusual vaginal bleeding or heavier than usual menstrual bleeding
  • vomit that looks like coffee grounds
  • frequent nose bleeds
  • coughing up blood
  • dry, red, painful, or irritated eyes
  • sensitivity to light
  • blurred vision, floaters, double vision, or other vision changes
  • wounds that do not heal
  • fever, sore throat, chills, or other signs of infection
  • changes in taste; muscle weakness; drooping eyelids or part of face; tingling, burning, pain, or loss of feeling in hands or feet
  • headache, seizures, confusion, problems thinking, or changes or loss of vision
  • decreased urination
  • extreme tiredness or weakness
  • weight gain
  • swelling of your face, hands, feet, ankles, or lower legs
  • pain, swelling, or tenderness in the abdomen (stomach area)
  • nausea
  • vomiting
  • ongoing pain that begins in the stomach area but may spread to the back

More common

  • Bladder pain
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blurred vision
  • chest pain
  • chills
  • cloudy urine
  • confusion
  • constipation
  • cough or hoarseness
  • coughing up blood
  • decreased urine output
  • difficult, burning, or painful urination
  • difficulty with breathing or swallowing
  • dilated neck veins
  • dizziness
  • fainting
  • frequent urge to urinate
  • increased menstrual flow or vaginal bleeding
  • indigestion
  • irregular breathing
  • joint pain, stiffness, or swelling
  • lightheadedness
  • lower back, side, or stomach pain
  • nervousness
  • nosebleeds
  • pains in the chest, groin, or legs, especially calves of the legs
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • pale skin
  • paralysis
  • pinpoint red spots on the skin
  • pounding in the ears
  • prolonged bleeding from cuts
  • rapid weight gain
  • rapid, shallow breathing
  • red or black, tarry stools
  • red or dark brown urine
  • severe headaches of sudden onset
  • slow or fast heartbeat
  • sore throat
  • sudden loss of coordination
  • sudden slurred speech
  • sudden vision changes
  • tingling of the hands or feet
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual weight gain or loss

Rare

  • Anxiety
  • burning, numbness, tingling, or painful sensations
  • chest discomfort
  • fast, pounding, or irregular heartbeat or pulse
  • pain, redness, or swelling in the arms or legs
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet
  • Blistering, peeling, loosening of the skin
  • bloody, black, or tarry stools
  • blue-green halos seen around objects
  • clay-colored stools
  • dark urine
  • decreased appetite
  • diarrhea
  • dry eyes
  • fever
  • headache
  • heartburn
  • indigestion
  • itching or skin rash
  • joint or muscle pain
  • loss of appetite
  • nausea and vomiting
  • red irritated eyes
  • red skin lesions, often with a purple center
  • sensitivity of the eyes to light
  • sensitivity to heat
  • severe vomiting, sometimes with blood
  • sore throat
  • stomach cramps or tenderness
  • sweating
  • trouble sleeping
  • unusual tiredness or weakness
  • vomiting of material that looks like coffee grounds, severe and continuous
  • weight loss
  • yellow eyes or skin

Drug Interactions

Pregnancy and Lactation

AU TGA pregnancy category D

Pregnancy

Based on its mechanism of action and findings in animals, Iclusig can cause fetal harm when administered to a pregnant woman [see Data]. There are no available data on Iclusig use in pregnant women. In animal reproduction studies, oral administration of ponatinib to pregnant rats during organogenesis caused adverse developmental effects at doses lower than human exposures at the recommended human dose [see Data]. Advise pregnant women of the potential risk to a fetus

Lactation

No information is available on the clinical use of ponatinib during breastfeeding. Because ponatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during ponatinib therapy and the manufacturer recommends withholding breastfeeding for 6 days following the last dose.[1]

How should this medicine be used?

Ponatinib comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take ponatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ponatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them. Your doctor may need to delay your treatment, adjust your dose, or permanently stop your treatment of ponatinib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take ponatinib even if you feel well. Do not stop taking ponatinib without talking to your doctor.

What special precautions should I follow?

Before taking ponatinib,

  • tell your doctor and pharmacist if you are allergic to ponatinib, any other medications, lactose, or any of the ingredients in ponatinib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: ketoconazole (Nizoral); medications to reduce stomach acid, such as lansoprazole (Prevacid); and rifampin (Rifadin, Rimactane, in Rifamate, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with ponatinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have or have ever had a bleeding problem; diabetes; pancreatitis (swelling of the pancreas, a gland behind the stomach that produces substances to help with digestion); or if you are lactose intolerant (inability to digest dairy products). Also, tell your doctor if you drink or have ever drunk large amounts of alcohol.
  • you should know that ponatinib may decrease fertility in women. However, you should not assume that you or your partner cannot become pregnant. Tell your doctor if you are pregnant or plan to become pregnant. If you are female, you will need to take a pregnancy test before you start treatment. You should use birth control to prevent pregnancy during your treatment with ponatinib and for 3 weeks after you stop taking the medication. Talk to your doctor about the types of birth control that will work for you. If you become pregnant while taking ponatinib, call your doctor immediately. Ponatinib may harm the fetus.
  • tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking ponatinib and for 6 days after your final dose.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking ponatinib. If you are scheduled to have surgery, your doctor will tell you to stop taking ponatinib for at least 7 days before the surgery or procedure. Your doctor will tell you when to start taking ponatinib again after your surgery.
  • you should know that your blood pressure may increase during your treatment with ponatinib. Your doctor will probably monitor your blood pressure during your treatment.

 

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203469s034lbl.pdf
  4. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-multiple-new-safety-measures-leukemia-drug-iclusig
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Ponatinib
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Ponatinib-hydrochloride
  7. https://www.cancer.gov/about-cancer/treatment/drugs/ponatinibhydrochloride
  8. https://www.webmd.com/drugs/2/drug-163095/ponatinib-oral/details/list-contraindications
  9. https://go.drugbank.com/drugs/DB08901
  10. https://en.wikipedia.org/wiki/Ponatinib
  11. https://medlineplus.gov/druginfo/meds/a613029.html
  12. https://www.drugs.com/dosage/ponatinib.html
  13. https://www.bindingdb.org/rwd/bind/info.jsp
  14. https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322535
  15. http://ctdbase.org/about/legal.jsphttps://ctdbase.org/detail.go?type=chem&acc=C545373
  16. http://www.dgidb.org/downloads
  17. https://www.dgidb.org/drugs/PONATINIB
  18. https://www.drugbank.ca/legal/terms_of_use
  19. https://www.drugbank.ca/drugs/DB08901
  20. https://www.guidetopharmacology.org/about.jsp#license
  21. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890
  22. https://www.guidetopharmacology.org/targets.jsp
  23. http://idrblab.net/ttd/data/drug/details/D0H0EQ
    PMID25656651-Compound-5
    http://idrblab.net/ttd/data/drug/details/D0WL1U
  24. https://creativecommons.org/licenses/by-nc/4.0/
    Ponatinib
    https://commonchemistry.cas.org/detail?cas_rn=943319-70-8
  25. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://chem.nlm.nih.gov/chemidplus/sid/0943319708
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  26. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Ponatinib
    https://comptox.epa.gov/dashboard/DTXSID50241426
    https://comptox.epa.gov/dashboard/chemical-lists/
  27. https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/297207
  28. https://www.fda.gov/about-fda/about-website/website-policies#linking
    PONATINIB
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4340891KFS
  29. Hazardous Substances Data Bank (HSDB)
    Ponatinib
    https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8184
  30. http://www.hmdb.ca/citing
    Ponatinib
    http://www.hmdb.ca/metabolites/HMDB0240214
    https://hmdb.ca/metabolites/HMDB0240214#spectra
  31. ChEBI
    Ponatinib
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:78543
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  32. https://www.fda.gov/about-fda/about-website/website-policies#linking
    PONATINIB
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  33. LiverTox
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Ponatinib
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Ponatinib/
  34. https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C95777
    https://ncit.nci.nih.gov
  35. .https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  36. Nature Chemical Biology
    https://pubchem.ncbi.nlm.nih.gov/substance/152146116
  37. https://www.ema.europa.eu/en/about-us/legal-notice
    https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001186-pip01-11-m02
  38. Drugs and Lactation Database (LactMed)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/NBK500859/
  39. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  40. https://creativecommons.org/licenses/by/4.0/
    https://www.norman-network.com/nds/SLE/
  41. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  42. MassBank of North America (MoNA)
    https://mona.fiehnlab.ucdavis.edu/documentation/license
    Ponatinib (AP24534)
    https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=
  43. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  44. https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    ponatinib
    https://rxnav.nlm.nih.gov/id/rxnorm/1364347
  45. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0LI
  46. https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  47. https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  48. SpectraBase
    Ponatinib
    https://spectrabase.com/spectrum/7lXGZjKeL9d
    Ponatinib
    https://spectrabase.com/spectrum/GAzuYubHCOH
    Ponatinib
    https://spectrabase.com/spectrum/6dSGRXL2rz4
  49. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=39053044-554133775
  50. https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=39053044-554134147
  51. https://creativecommons.org/publicdomain/zero/1.0/
    https://www.wikidata.org/wiki/Q198728
  52. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    ponatinib
    https://www.ncbi.nlm.nih.gov/mesh/67545373
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
    Antineoplastic Agents
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    https://www.ncbi.nlm.nih.gov/mesh/68047428
  53. https://www.kegg.jp/kegg/legal.html
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    Drug Groups
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  54. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    GHS Classification Tree
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  55. http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  56. PATENT SCOPE (WIPO)
    https://pubchem.ncbi.nlm.nih.gov/substance/391191658
  57. NCBI
    https://www.ncbi.nlm.nih.gov/projects/linkout

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Ponatinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.